David Chun-Leung Chau1, David Wang2, Alissa Tedesco2
1University of Waterloo, Waterloo, Ontario.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Most prostate cancer patients prefer intermittent androgen deprivation therapy (IAD) over continuous androgen deprivation therapy (CAD). Quality of life significantly influences this preference, though opinions on side effects diverge.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: